INFOGRAPHIC: The Cancer R&D Landscape
Executive Summary
Recent advances in immune-oncology have dominated the headlines in cancer research over the past year or so. The rise in these products largely accounts for the increase in numbers of oncology drug candidates in development, but they still only account for 13% of medicines being actively developed in cancer indications. Here Scrip takes a step back to look at a few facts and figures from the wider cancer R&D field.